# To everyone who watched someone bleed and couldn't stop it > Introduction: one second, not one hour - Author: Maxime Marquette - Publisher: MadMax (https://mad-max.co) - Section: Open letter - Published: 2026-07-04 - Canonical URL: https://mad-max.co/en/article/a-ceux-qui-ont-vu-quelquun-saigner-sans-pouvoir-larreter ## Introduction: one second, not one hour ### What it changes to count in seconds Dear reader, I'm writing to you the way you write to someone who has already stood terrified in front of a **wound** that refused to close. You may have lived through it: a fall, a workplace accident, a surgical procedure gone wrong, and that terrible feeling that **time** is speeding up while **help** never seems to arrive fast enough. That exact gap between the **injury** and the treatment is what **South Korean researchers** at **KAIST**, the **Korea Advanced Institute of Science and Technology**, have just narrowed, perhaps dramatically. Their **discovery** is called, simply, **AGCL powder**. The name means nothing to the **public**, but the effect is immediate: sprayed onto a heavily bleeding **wound**, this powder turns into a **solid gel** in **about one second**, according to **data** published by the team led by **Professor Steve Park**, of the materials **science** department, and **Professor Sangyong Jon**, of the department of biological sciences at **KAIST**. ### Why I'm writing you a letter instead of a plain summary I could simply hand you the raw numbers and move on. But this subject touches me because it speaks to a universal moment: the instant you feel powerless in front of someone else's body losing its **blood**. **Soldiers** live it on the battlefield, **surgeons** live it in the operating room, **parents** live it when a child falls. This letter is addressed to all of them, with the promise that I won't twist a single result to impress you. I'm going to lay out what the **science** actually claims, what it cannot yet claim, and why that distinction matters just as much as the **discovery** itself. *Let me say this upfront: one second in a **lab** is not yet one second in a packed emergency room, and I refuse to sell you a miracle before its time.* ## The mechanics of a chemical miracle, explained simply ### A powder that reacts on contact with blood The **AGCL powder** owes its name to its components: **alginate**, **gellan gum**, and **chitosan**, three naturally derived materials, combined with a cross-linking agent, **glutaraldehyde**. According to the **KAIST** university publication sheet, this blend reacts with the **calcium ions** naturally present in **blood** to form, in roughly one second, an adhesive **hydrogel** network capable of absorbing up to **725%** of its own weight in **blood**, according to the **KAIST** scientific publication page (see Sources). This isn't just another bandage. It's a system that turns the **chemistry** of **blood** itself into the trigger. **Professor Steve Park** and his team set out to solve a very concrete problem: standard dressings often fail on deep, irregular wounds or on wounds located in areas that are hard to compress. ### An adhesion that holds, even under pressure What sets this powder apart isn't just its **speed**, it's its **bonding strength**: more than **40 kPa** according to published **data**, a level the authors compare to firm manual pressure applied directly to the **wound**. In the trials presented, the powder outperformed **TachoSil**, a reference **hemostatic** agent already used clinically, in reducing both the volume of **blood** lost and the **time** needed to stop the bleeding. The **researchers** also report a hemolysis rate below **3%**, cell viability above **99%**, and antibacterial efficacy exceeding **99%** — biological safety indicators that, on paper, are reassuring. *I have to confess something: the first time I read these numbers, my instinct was skepticism, not wonder. Labs announce miracles every week.* ## Where this research comes from, and why now ### A field context, not just a lab one A notable detail: the **research** team included an active-duty **army major**, according to the **KAIST press center**. That military involvement isn't incidental. It places this **innovation**, right from the start, within a logic of **battlefield survival**, where massive hemorrhage remains one of the leading preventable causes of death on a **battlefield** or during a major industrial accident. The **New York Post** picked up the announcement, emphasizing its potential for extreme emergency situations, from the **battlefield** to natural disasters, according to a report published in **February 2026** (see Sources). This dual vocation, civilian and military, partly explains why the news traveled so fast through international media. ### A striking stability under extreme conditions Another technical detail worth noting: the powder reportedly keeps its properties for about **24 months** at room temperature, even in humid environments, according to **data** published by the **KAIST researchers**. That storage durability is crucial for a product meant to be carried in a medical bag, a military vehicle, or a community **first-aid** kit, far from a **lab** refrigerator. This ability to withstand harsh conditions isn't a cosmetic detail: it's often what separates a **lab discovery** from a tool that's actually usable in the field, years down the road. *This durability strikes me more than the **speed** itself, because a fragile product never survives the chaos of a real emergency.* ## What the trials actually showed, without exaggeration ### Animal models, not human trials yet Let's be honest here: the spectacular results come from **preclinical models**, notably trials on liver injuries in animals. According to the **KAIST** report, liver function reportedly returned to normal about **two weeks** after the intervention, with no sign of systemic toxicity detected during the observation period. That's encouraging, but it's not the same as a **controlled clinical trial** in humans. The distinction matters enormously for anyone hoping to see this product on a pharmacy shelf next year: it's probably not happening anytime soon. ### The still-long road to regulatory approval None of the sources consulted for this letter mention an approval date from any **regulatory agency**, whether in **South Korea**, the **United States**, or **Europe**. At this stage, the product remains a university **research** result published in a scientific journal, not a marketed medical device. This lack of information shouldn't be read as a failure, just as a plain fact: developing a **hemostatic** product for widespread human use historically takes several years between the initial publication and market launch. *Here, I choose caution over easy excitement. I've seen too many viral headlines sell a mouse-model **discovery** as a human treatment by the next morning.* ## Why stopping a severe hemorrhage is a matter of life and death ### The time factor in emergency medicine In the **trauma medicine** literature, uncontrolled massive hemorrhage remains one of the leading preventable causes of death, whether on a **battlefield**, in a car accident, or during a complex surgical procedure. Every minute gained in controlling the bleeding statistically increases the patient's chances of **survival**. It's this context that gives real weight to an **innovation** that promises to shrink that delay from several minutes to a few seconds, even though, again, that promise remains rooted in **preclinical trials**. ### The limits of traditional dressings Classic **compression dressings** require sustained manual pressure and perform poorly on deep, irregular wounds or wounds located in hard-to-reach anatomical areas, like the neck or the groin. That's precisely the gap the **AGCL powder** aims to fill, by conforming to the shape of the **wound** rather than trying to compress it from the outside. This geometric adaptability, if confirmed in clinical practice, could represent a genuine advantage in the field, particularly for **first responders** trained in pre-hospital emergency care. *I think here of all the paramedics and military doctors I've never personally met, whose everyday work could one day be changed by this powder.* ## What the comparison with existing hemostatics tells us ### TachoSil and today's commercial hemostatic agents **TachoSil**, used as the point of comparison in the **KAIST** trials, is already a recognized clinical **hemostatic** product, made of **collagen** and **clotting factors**. The fact that AGCL powder shows, according to published data, better performance on certain measures — **time** to hemostasis, volume of blood lost — is an encouraging signal, but it comes from a single set of experiments, not a large-scale comparison. Scientific caution demands multiple independent trials before declaring definitive superiority over products already proven for years in the operating room. ### The advantage of a powder format over patches Existing hemostatic agents often come as **patches** or **sponges**, poorly suited to non-flat surfaces. The powder format, by contrast, naturally conforms to the contours of a **wound** regardless of its geometry, which could widen its range of applications beyond the classic injuries studied in the **lab**. This flexibility of use partly explains the enthusiasm of specialized media, without guaranteeing a perfect translation to human clinical reality. *I note, with a touch of admiration, that the simplicity of a single gesture — spraying a powder — hides remarkably sophisticated **chemistry** behind it.* ## The international media echo, between accuracy and hype ### Rapid worldwide coverage Since **KAIST**'s initial announcement in late December 2025, the news has been picked up by numerous outlets, from the **New York Post** to **ScienceDaily**, along with specialized health and defense outlets, including **ScienceDaily**'s health section. This rapid spread illustrates the **public**'s appetite for spectacular medical advances, especially ones touching a need as universal as stopping a hemorrhage. But this virality carries a risk: turning a promising **research** step into an immediate commercial promise, when the product has not yet cleared the regulatory steps needed to reach the market. ### The role of social media in amplification Posts on professional platforms, including some shared by pharmacology experts, helped spread this information well beyond the initial academic circle, as illustrated by a professional post on **LinkedIn** dated February 2026. This dynamic shows just how fast a scientific **discovery** can now travel — at a pace that far outstrips the much slower rhythm of clinical validation. I believe it's our collective responsibility, as readers as much as columnists, to slow down this rush to hype and give nuance its rightful place. *I note, not without a touch of irony, that this news spread across social networks far faster than a medical product moves through regulatory steps.* ## The military applications, a reality worth naming ### An innovation also designed for the battlefield The participation of a **military officer** on the **research** team confirms that this powder was designed, from the outset, with combat wounds in mind. In a world where several active conflicts continue to produce casualties from uncontrolled hemorrhage, a fast, lightweight, and time-stable solution represents an obvious strategic interest for armed forces, whether South Korean or allied. This defense dimension takes nothing away from the discovery's civilian reach; it broadens it, showing that the same constraints — speed, stability, ease of use — apply just as much to a wounded soldier as to a victim of a domestic accident. ### A common thread with other innovations in war trauma care Other international research into **next-generation hemostatics**, notably in gastroenterology, is exploring similar approaches to rapid gelling on contact with biological fluids. This parallel confirms that the chemical path explored by **KAIST** fits within a broader scientific trend, not an isolated case. This international convergence, to my mind, reinforces the credibility of the overall approach, even though each product must be evaluated individually on its own data. *This military dimension doesn't bother me: saving a wounded soldier's life deserves just as much attention as saving a civilian's, and the two uses feed each other.* ## What this discovery means for tomorrow's civilian medicine ### Potential applications well beyond the battlefield If this powder ever clears the approval process, its uses could extend to emergency rooms, ambulances, family **first-aid** kits, and even remote areas where reaching a **hospital** takes time. Picture a hiker injured in the mountains, a worker hurt on an isolated job site, or a car-accident victim in a rural region: in every one of these cases, a simple, stable, fast hemostatic tool could literally make the difference between life and death. It's this universal reach, far beyond the military context alone, that makes this **research** worth the general **public**'s attention, not just that of defense or surgery specialists. ### The questions that remain unanswered How much will this powder cost once commercialized? Will it be accessible to public health systems, or reserved for specialized markets? What will future human trials show? None of the sources consulted answer these questions today, and it would be dishonest of me to pretend otherwise. I'd rather tell you clearly what I don't know than sell you manufactured certainties. That, I believe, is the least I owe you in this letter. *If I had to sum up my state of mind in one phrase, it would be: cautious hope. Not the euphoria of viral headlines, nor systematic cynicism either.* ## What this story tells us about the global scientific race ### South Korea, a rising hub of biomedical innovation **KAIST** has established itself over the past several years as a major research hub in Asia, rivaling leading Western institutions across fields as varied as **advanced materials**, **robotics**, and now applied **biomedicine**. This discovery fits within a broader dynamic of international scientific competition, where each advance boosts the academic and industrial prestige of the country that produces it. For the **West**, this South Korean acceleration is both a valuable potential partnership, with **South Korea** remaining a major strategic ally, and a reminder that breakthrough **innovation** is no longer confined to American or European labs alone. ### A method lesson for evaluating viral discoveries This story teaches us, once again, a simple method: check the **primary source**, distinguish **preclinical trials** from clinical ones, and resist the temptation of a headline promising an immediate miracle. This rigor takes nothing away from the legitimate wonder such an advance inspires; it simply makes it more solid, more lasting. It's this rigor that I've tried to apply throughout this letter, hoping it will be useful the next time a spectacular headline crosses your feed. *I see in this scientific competition a reason for optimism rather than worry: when several global hubs innovate in parallel, all of humanity advances faster.* ## What competing scientists think ### A chemical approach that isn't entirely isolated Other international teams, notably in China and the United States, are exploring similar paths of rapid gelling for managing hemorrhages, whether for surgical wounds, digestive bleeding, or war injuries. This global scientific competition on this exact terrain shows just how much the problem of uncontrolled hemorrhage remains a **major challenge** for modern medicine, despite decades of progress in trauma care. This convergence of multiple efforts, rather than diluting **KAIST**'s credit, actually confirms the relevance of its approach: when several independent teams converge on comparable solutions, it's often a sign that a real scientific problem is being collectively solved. ### The need for independent replication No scientific discovery, however promising, becomes an established truth without being reproduced by teams independent of the one that first published it. That's a fundamental rule of the scientific method, often forgotten in the rush toward viral news. I'll be watching for any replication studies conducted by other labs, in **South Korea** or elsewhere, before treating these results as definitively established. *I'll always prefer a scientific truth confirmed twice over a spectacular discovery announced once, even if the second option gets fewer views on social media.* ## What this means for caregivers and families ### A tool that could one day equip family kits Beyond hospitals and battlefields, one can imagine, in the very long term, a consumer version of this technology, adapted for family **first-aid** kits. That scenario remains hypothetical at this stage, but it illustrates the potential reach of an **innovation** initially designed for extreme contexts. Parents, summer camp counselors, sports coaches: all could, in theory, one day benefit from a tool as simple to use as an aerosol can, to manage a serious **injury** while waiting for professional **help**. ### The role of first-aid training However effective a future commercial product may be, it will never replace proper **first-aid** training. Knowing how to recognize a **severe hemorrhage**, calling for help quickly, and applying the right steps remains essential, with or without a miracle powder. This discovery should never serve as an excuse to neglect learning basic **first-aid** steps, which remain the first line of defense against bleeding emergencies. *I'll say it plainly: no powder, however fast, will ever replace a bystander who can keep their composure and call for help at the right moment.* ## What patient-safety experts will watch closely ### The question of long-term toxicity One point future studies will absolutely need to clarify concerns the **long-term toxicity** of the formed **gel**, once it stays in the body beyond the two weeks observed in animals. **KAIST researchers** report no systemic toxicity during the studied period, but longer follow-up will be needed to fully reassure future regulators. That's a point worth keeping in mind if you hear about this powder again in the coming months: real validation will come from human trials, not from animal data alone, however encouraging. ### The question of cost and future accessibility No pricing information has been published to date, which makes any discussion of accessibility for public health systems or more modest military budgets premature. The history of medical innovations shows that a breakthrough product's initial price can vary enormously depending on later industrial choices and manufacturing partnerships. I'll be watching this question closely, because a discovery that saves lives in the **lab** changes nothing in reality until it becomes accessible to those who need it in the field. *I firmly believe a medical **innovation** only has real value once it reaches the hands of those who need it, not just the pages of a prestigious scientific journal.* ## What this discovery says about our collective relationship with risk ### Why a lab innovation fascinates us so much There's something profoundly human in our fascination with a technology that can stop bleeding in one second: it touches our oldest fear, that of losing our life to an **injury** we cannot control. This **ancestral fear** explains why a materials **chemistry** discovery, seemingly very technical, resonates so widely with the general public. **KAIST**, by publishing its results, unintentionally struck a universal nerve: no one is safe from a serious **injury**, whether at home, on the road, or at work. ### The media's duty of responsible science communication Faced with this kind of news, the media, myself included, carries a particular responsibility: to convey scientific enthusiasm without ever turning a preliminary result into a firm promise. It's a constant balancing act between public interest and factual rigor. I strive, in this letter as in my other pieces, to hold that balance, even knowing the most cautious headline is never the one that gets the most shares. *I'd rather write an honest piece that circulates less than a spectacular one that betrays scientific reality. That's an editorial choice I'd make again every time.* ## Conclusion: what I take away, and what I wish for you ### A measured hope, not a promise This letter is drawing to a close, and I want to be honest to the very end: **KAIST**'s **AGCL powder** represents a real, published, peer-reviewed scientific advance, potentially significant for tomorrow's trauma medicine. But it is not yet a treatment available at your neighborhood pharmacy, nor a clinically validated certainty in humans. I choose to pass this hope on to you with its limits clearly stated, because I believe that's how trust is built, one verified fact at a time. ### What I wish for you, as I close this letter I hope you never have to test, in an emergency, the effectiveness of any hemostatic. But should that day come, for you or a loved one, know that part of the scientific world is working, quietly but seriously, to shrink the gap between injury and treatment. That may be the most reassuring news I can offer you today. *I close this letter with one simple certainty: **science** often advances in small, silent steps, long before the general public hears about it.* **By Maxime Marquette, columnist** ## Columnist's transparency note ### Editorial stance I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies. I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events. ### Method and sources This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here. **Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies. **Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations. When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**. ### Nature of the analysis The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted. My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors. This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text. ## Sources ### Primary sources - [ScienceDaily — release on the KAIST hemostatic powder, June 2026](https://www.sciencedaily.com/releases/2026/06/260625014835.htm) - [KAIST Pure — scientific publication page for the AGCL study, 2026](https://pure.kaist.ac.kr/en/publications/an-ionic-gelation-powder-for-ultrafast-hemostasis-and-accelerated/) - [New York Post — report on the South Korean hemostatic powder, February 7, 2026](https://nypost.com/2026/02/07/us-news/south-korean-scientists-create-life-saving-spray-to-stop-bleeding-instantly/) - [KAIST News Center — official announcement of the discovery, December 29, 2025](https://news.kaist.ac.kr/newsen/html/news/?mode=V&mng_no=56690) ### Secondary sources - [LinkedIn — pharmacology expert's post sharing the study, February 2026](https://www.linkedin.com/posts/prof-ruchi-tiwari-26668141_researchers-in-south-korea-specifically-activity-7427243101339099136-O9pB) - [ScienceDaily — health and medicine section](https://www.sciencedaily.com/news/health_medicine/) - [WION Podcast — video report on the hemostatic powder, January 2026](https://www.youtube.com/watch?v=s6GjXEoISi4) - [My Modern Met — detailed analysis of the AGCL discovery, January 2026](https://mymodernmet.com/agcl-spray-on-powder-stops-severe-bleeding/) --- Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/a-ceux-qui-ont-vu-quelquun-saigner-sans-pouvoir-larreter